Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Pipeline Review, H1 2017

  • ID: 4311845
  • Report
  • 25 pages
  • Global Markets Direct
1 of 5
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 7 is an enzyme that is encoded by the MAP3K7 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signal transduction of TRAF6, various cytokines interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR).

The report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017' outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Genetic Disorders and Ophthalmology which include indications Inflammation, Chronic Inflammation, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pancreatic Cancer and Proliferative Vitreoretinopathy (PVR).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)
  • The report reviews Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Overview
  3. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Companies Involved in Therapeutics Development
  14. Astellas Pharma Inc
  15. Chugai Pharmaceutical Co Ltd
  16. Confluence Life Sciences Inc
  17. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Drug Profiles
  18. Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile
  19. Product Description
  20. Mechanism Of Action
  21. R&D Progress
  22. Small Molecule to Inhibit TAK1 for Inflammation - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. Small Molecule to Inhibit TAK1 for Ovarian Cancer - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. Small Molecules to Inhibit TAK1 for Arthritis, Genetic Disorders, Chronic Inflammation and Pancreatic Cancer - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. Small Molecules to Inhibit TAK1 for Inflammation and Oncology - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Dormant Products
  39. Appendix
  40. Methodology
  41. Coverage
  42. Secondary Research
  43. Primary Research
  44. Expert Panel Validation
  45. Contact Us
  46. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by Astellas Pharma Inc, H1
  12. Pipeline by Chugai Pharmaceutical Co Ltd, H1
  13. Pipeline by Confluence Life Sciences Inc, H1
  14. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Stage and Routes of Administration, H1
  6. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Chugai Pharmaceutical Co Ltd
  • Confluence Life Sciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll